This article is more than 5 years old. Information may no longer be current.
FDA grants accelerated approval to Opdivo for classical Hodgkin lymphoma
The FDA today granted accelerated approval to nivolumab for treatment of certain patients with classical Hodgkin lymphoma.
Nivolumab (Opdivo, Bristol-Myers Squibb) is indicated for patients who relapsed or progressed after autologous hematopoietic stem cell transplant (HSCT) and posttransplant brentuximab vedotin (Adcetris, Seattle Genetics).
The agency recommended a dose schedule of 3 mg/kg nivolumab via IV every 2 weeks until disease progression or unacceptable toxicity.
The FDA based the approval in part on results of two single-arm, multicenter trials that evaluated nivolumab in this patient population, regardless of PD-L1 expression.
Objective response rate served as the primary endpoint. Duration of response served as a secondary outcome measure.
Efficacy analyses included 95 patients who had undergone a median five prior systemic regimens (range, 3-15) and received a median 17 doses (range, 3-48) of nivolumab.
Researchers reported a 65% (95% CI, 55-75) objective response rate; 58% of patients achieved partial remission and 7% achieved complete remission.
Median time to response was 2.1 months, and estimated median duration of response was 8.7 months.
Safety analyses included 263 patients, 98% of whom had undergone autologous HSCT. These patients received a median 10 doses (range, 1-48) of nivolumab.
Adverse reactions reported in at least 20% of the patient population included fatigue, upper respiratory tract infection, cough, pyrexia and diarrhea. Other adverse reactions reported in at least 10% of patients included rash, pruritus, musculoskeletal pain, nausea, vomiting, abdominal pain, headache, peripheral neuropathy, arthralgia, dyspnea, infusion-related reactions and hypothyroidism or thyroiditis.
Twenty-one percent of patients experienced serious adverse reactions, the most common of which were pneumonia, pleural effusion, pneumonitis, pyrexia, infusion-related reaction and rash.
A new “warning and precaution” label was issued for complications of allogeneic HSCT after nivolumab. The label urges health care professionals to follow patients closely for early evidence of transplant-related complications, including hyperacute graft-versus-host disease, severe acute GVHD, steroid-requiring febrile syndrome, hepatic veno-occlusive disease and other immune-mediated adverse reactions.
The FDA has required Bristol-Myers Squibb to further evaluate the safety of allogeneic HSCT after nivolumab.